Background
Liver cirrhosis is recognized with long-term follow-up of patients
after the Fontan procedure. The effect of liver cirrhosis on the use of
heart transplant (HT) and on post-HT outcomes is unknown.
Methods
We reviewed Fontan patients evaluated for HT from 2004 to 2012 with
hepatic computed tomography (CT) imaging, classified as normal,
non-cirrhotic changes, or cirrhosis. The primary outcome was 1-year
all-cause mortality, and the secondary outcome was differences in serial
post-HT liver evaluation.
Results
CT imaging in 32 Fontan patients evaluated for HT revealed 20
(63%) with evidence of liver disease, including 13 (41%)
with cirrhosis. Twenty underwent HT, including 5 non-cirrhotic and 7
cirrhosis patients. Characteristics at listing between normal or
non-cirrhotic (n = 13) and cirrhosis
(n = 7) groups were similar, except cirrhosis
patients were older (median 17.6 vs 9.6 years, p =
0.002) and further from Fontan (median 180 vs 50 months, p
< 0.05). Serial liver evaluation was similar, including aspartate
aminotransferase, alanine aminotransferase, bilirubin, albumin, and
tacrolimus dose at 1, 3, 6, 9, and 12 months. Overall patient survival was
80% at 1 year, with no difference between cirrhosis and
non-cirrhosis patients (86% vs 77%, p
= 0.681). Liver biopsies were performed in 7 patients before HT, and
all specimens showed architectural changes with bridging fibrosis.
Conclusions
Most patients evaluated for HT had abnormal liver findings by CT,
with cirrhosis in 41%. One-year mortality and serial liver
evaluation were similar between groups after HT. Liver cirrhosis identified
by CT imaging may not be an absolute contraindication to HT alone in this
population.
The current study examined cardiac denial and psychological predictors (i.e., depression, anxiety) of health outcomes including medical nonadherence and physical health in a sample of 80 adults with congenital heart disease (ACHD). Results indicated that denial of impact was elevated in this patient group compared with reference groups, and denial was negatively associated with depression and anxiety at ps < .01. Results indicated that depression, anxiety, and denial predicted unique variance in medical nonadherence, and gender moderated the relationships between these psychological factors and nonadherence. For depression, men and women showed similar relationships between depression and nonadherence at high levels of depression; however, at low levels of depression (i.e., a more normal mood state), men were less adherent compared with women. For anxiety, men and women did not differ in adherence at low levels of anxiety; however, men experiencing high anxiety were less adherent compared with women experiencing high anxiety. Implications of this study are discussed including the role of gender and denial and the impact of denial functioning to reduce negative affect. Depression was the only significant predictor of physical functioning. Results of this study suggest that psychological interventions aimed at depression and anxiety may function differently across gender to improve patient medical adherence and improve physical functioning in ACHD.
Abstract. Hemophagocytic lymphohistiocytosis (HLH) and rhabdomyolysis are rare complications of typhoid fever from Salmonella enterica serovar Typhi. Herein, we describe the clinical features in a 21-year-old female from India who presented to the intensive care unit with fever, severe pancytopenia, and rhabdomyolysis.
The epidemic of obesity has contributed to a growing burden of metabolic syndrome (MetS) and diabetes mellitus (DM) worldwide. MetS is defined as central obesity along with associated factors such as hypertriglyceridemia, low high-density lipoprotein cholesterol, hyperglycemia, and hypertension. MetS and DM are associated with significant cardiovascular morbidity and mortality. Healthy behavioural modification is the cornerstone for reducing the atherosclerotic cardiovascular disease burden in this population. Comprehensive, multi-disciplinary cardiac rehabilitation (CR) programs reduce mortality and hospitalizations in patients with MetS and DM. Despite this benefit, patients with MetS and DM are less likely to attend and complete CR because of numerous barriers. Implementation of innovative CR delivery models might improve utilization of CR and cardiovascular outcomes in this high-risk population.
Background: There is growing interest in using dietary supplements to delay fatigue, accelerate recovery time, and improve the performance of athletes. Objectives: In the present study, we investigated the effect of beta-alanine supplementation on the levels of some metabolic indexes related to recovery and the performance of soccer players. Methods: Sixteen young soccer players [age: 20 ± 1.19 years, weight: 67.67 ± 8.9 kg, height: 176.38 ± 5.54 cm and body mass index (BMI): 21.76 ± 2.12 kg/m2] completed this study. The subjects were randomly assigned into two groups. They were supplemented with 5g/day beta-alanine (BA) (BG, N = 8) or placebo (PG; N = 8; maltodextrin) for three weeks. Maximum oxygen consumption, explosive power, and recovery-related blood parameters (creatine kinase, lactate dehydrogenase, urea) were measured in two stages before and after supplementation. Results: No significant change was observed in the serum creatine kinase level after the intervention (P = 0.061). Also, no significant difference was observed in serum levels of other blood factors, such as lactate dehydrogenase (P = 0.061) and urea (P = 0.061). Regarding performance factors, no significant changes were observed in aerobic power (P = 0.061) and explosive power (P = 0.061). Conclusions: Our results suggest that beta-alanine has no effect on reducing metabolic factors related to recovery and may improve the aerobic power of soccer players.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.